BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

BeiGene, a Beijing oncology company, has enrolled the first patient in a China Phase III trial of pamiparib (BGB-290), a PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. The drug will be administered as a maintenance therapy in patients whose ovarian cancer has recurred. Pamiparib is also being tested as a monotherapy and in combination regimens for a variety of solid tumor malignancies. BeiGene pointed out that, to date, there are no PARP inhibitors approved for China use. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:

Original Article: BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

More From BioPortfolio on "BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients"